Cardiosight®-S

Cardiosight®-SFunctional human cells derived
from iPSCs

hiPSC-derived Cardiomyocytes

CAT# Product Description Product Capacity
C-001 NEXEL Cardiosight®-S Kit, small

1. Cardiosight®-S, Cryopreserved hiPSC-derived Cardiomyocytes
2. Cardiosight®-S Media (CM-001, 100 ml)
3. Cardiosight®-S Maintenance Supplement (CS-001, 2 ml)
4. Cardiosight®-S Plating Supplement (CS-010, 0.6 ml)
≥ 2.5 × 10⁶ Viable cells / Vial
C-002 NEXEL Cardiosight®-S Kit, large

1. Cardiosight®-S, Cryopreserved hiPSC-derived Cardiomyocytes
2. Cardiosight®-S Media (CM-002, 200 ml)
3. Cardiosight®-S Maintenance Supplement (CS-001, 2 ml X2)
4. Cardiosight®-S Plating Supplement (CS-020, 0.9 ml)
≥ 5 × 10⁶ Viable cells / Vial
CMS-001 1. Cardiosight®-S Media (CM-001, 100 ml)
2. Cardiosight®-S Maintenance Supplement (CS-001, 2 ml)
3. Cardiosight®-S Plating Supplement (CS-010, 0.6ml)
100 ml
CMS-002 1. Cardiosight®-S Media (CM-002, 200 ml)
2. Cardiosight®-S Maintenance Supplement (CS-001, 2 ml X 2)
3. Cardiosight®-S Plating Supplement (CS-020, 0.9ml)
200 ml
  • All NEXEL products originate from a single male Caucasian iPS cell line reprogrammed in- house. Documentation concerning the origin of the cells is available upon request.

Cardiosight®-S Characteristics

Ready to Use

  • Quick recovery after thawing
  • Start to beat synchronously within 2~3 days
  • Ready for most assays by day 7

Consistent Quality

  • Consistently high quality, ISO9001 certified
  • Self-developed QC process focusing on electrophysiology
  • Low batch-to-batch, vial-to-vial variability

High Sensitivity

  • Easy detection of changes to electrophysiology by drug treatment
  • Serum-free media prevents unwanted interactions

Validation

  • Electrophysiology validated on multiple platforms
  • Multiple collaborations
  • Average Beat Interval (over 20 lots)
    1.15 ± 0.04 s (51.88 ± 1.7 bpm)
  • Average FPDcF (over 20 lots)
    402.1 ± 16.3 ms
  • “NEXEL’s cardiomyocytes are of the highest quality”
  • “Electrophysiological effects were appropriate and very consistent”
    - User reviews from online survey

Cardiosight®-S Quality Control

Cell Culture
Double validation using Trypan Blue and fluorescent dye
Plating efficiency & cell size soon to be added
Stable population over several weeks (depending on culture conditions)

100X

DIV7/ Video

DIV3

DIV7

DIV14

  • Cardiosight®-S cells were plated at 100,000 cells/cm² density in a 12-well plate and cultured using Cardiosight®-S Maintenance Media (full changes every other day)
Purity / Identity
> 93% +cTnT (Flow Cytometry)
Correct localization of Cx43
Ratio of Ventricular : Atrial : Nodal Cells = ~80 : ~19 : ~1

30,000 Cardiosight®-S cells were seeded on a 9 mm coverslip and cultured using Cardiosight®-S Maintenance Media (full changes every other day) for seven days. Immunostaining was performed at the concentrations recommended by the respective suppliers 1 hour at RT.

  • 100X
  • DIV 7
  • cTnT
  • Cx43
  • Merge (+DAPI)
  • MLC-2V
  • MLC-2A
  • Merge (+DAPI)
Electrophysiology & Drug Response
Using the Axion Maestro MEA (soon to add Nanion CE96)
Stable response over ~24 hour experiment
No change in response to 0.1% DMSO
Standardized response to select list of ion channel blockers

50,000 Cardiosight®-S cells are seeded as a 5 µl drop in Axion CytoView 48-well MEA plates. Cardiosight®-S Media is changed every other day and at least 3 hours prior to drug treatment. Baseline measurements are taken after pipetting 10% of the well volume exactly 2 times. All drugs were diluted in media immediately before treatment and then treated by a 10% media change. Measurements were taken at 5 minutes and 25 minutes after treatment.

  • DMSO (0.1%, 10% media change)
  • Mexiletine (NaV blocker)
  • Nifedipine (CaV blocker)
  • E4031 (hERG blocker)
Consistent between electrodes
Signal shape is highly consistent.
Synchrony between all electrodes.